Brokerages Set Shattuck Labs, Inc. (NASDAQ:STTK) Price Target at $4.00

Shattuck Labs, Inc. (NASDAQ:STTK) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $4.00.

A number of research analysts have recently commented on STTK shares. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Monday, December 1st. Wedbush assumed coverage on shares of Shattuck Labs in a research note on Monday, September 8th. They set an “outperform” rating and a $4.00 price target on the stock. Wall Street Zen upgraded shares of Shattuck Labs from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Wednesday, October 8th.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $3.15 on Wednesday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $3.38. The company has a market capitalization of $199.33 million, a price-to-earnings ratio of -3.09 and a beta of 1.70. The business has a 50-day moving average of $2.25 and a 200-day moving average of $1.62.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $1.00 million for the quarter. Research analysts expect that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen LLC purchased a new position in shares of Shattuck Labs during the 1st quarter valued at approximately $50,000. ADAR1 Capital Management LLC acquired a new stake in Shattuck Labs in the first quarter valued at $97,000. AQR Capital Management LLC raised its holdings in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Shattuck Labs during the 1st quarter valued at $81,000. Finally, Acadian Asset Management LLC grew its holdings in Shattuck Labs by 27.6% during the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after acquiring an additional 55,687 shares in the last quarter. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.